Financings in Brief: Genzyme
This article was originally published in The Gray Sheet
Genzyme: Announces public offering of 2.5 mil. shares of its General Division common stock at $51.25 per share. Anticipated proceeds will go toward "general corporate purposes, including possible future acquisitions or reacquisitions of technology, product rights, and distribution rights," the firm states. CS First Boston, Cowen & Co., Lehman Brothers and PaineWebber are co-managing the offering...
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.